Cytodyn Inc (CYDY)

[Bunny3999]

bluefish, leronlimab s mentioned several times with evaluation of positive outcome:

●CCR5を阻害薬によるCOVID-19の過剰免疫の是正
すでに抗HIV薬として承認されているマラビロクが使える？？
→CCR5阻害薬でRANTESの作用をブロックすると、IL-6の減少、CD8細胞数の回復とともにウイルス量が減少するようです。
突然登場のCCR5阻害薬ですが、理屈はこうです。

— influenzer (@influenzer3) May 19, 2020

https://publish.twitter.com/?query=https%3A%2F%2Ftwitter.com%2Finfluenzer3%2Fstatus%2F1262725427690303488&widget=Tweet

Elevated IL-6 and CCL5 (RANTES), decreased CD8 cell count and SARS-CoV-2 viral hemorrhage were observed in 10 patients with severe COVID-19. The figure shows that not only IL-1, IL-6, and IL-8, but also RANTES also increased in relation to severity.

Following administration of the CCR5 inhibitor leronlimab, the CCR5 inhibitor can inhibit its action because it works in conjunction with complete inhibition of the CCR5 receptor in macrophages and T cells and - significant confirmation significant confirmation significant confirmation significant confirmation significant confirmation - confirmation confirmation - confirmation - confirmation - confirmation - confirmation

May 19
ANSWER TO.
@ influenzer3
The figure shows (a) a decrease in IL-6, (b) an increase in CD8 cells, and (c) the resulting normalization of the CD4/8 ratio over time after treatment.

May 19
Consistent with the decrease in IL-6, single cell RNA sequencing showed a decrease in cluster of myeloid cells expressing IL-6 and its related genes. This is a new approach to reduce viral hemorrhage by disrupting the CCL5-CCR5 axis through positive immunosuppression and immunization.

CYDY's patents are related to CCL5 Inhibition, and is included in the footnotes of the since withdrawn patent regarding malavilock. CYDY's pending patents can be found here:

https://patents.google.com/patent/US20190002571A1/en